Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Kirwan

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
European Journal of Heart Failure|September 20, 2018
Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the interventionFriedrich Koehler, Kerstin Koehler, Oliver Deckwart, et al.
Nutrients|March 12, 2022
Effects of an Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides on Growth, Tolerability, Safety and Infection Risk in Infants with Cow's Milk Protein Allergy: A Randomized, Multi-Center TrialYvan Vandenplas, Marta Żołnowska, Roberto Berni Canani, et al.
International Journal of Cardiology|October 11, 2011
Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trialFriedrich Koehler, Sebastian Winkler, Michael Schieber, et al.
Circulation|April 13, 2023
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup AnalysisGerasimos Filippatos, Piotr Ponikowski, Dimitrios Farmakis, et al.
European Journal of Heart Failure|April 25, 2017
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysisStefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, et al.
JACC. Basic to Translational Science|December 14, 2021
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized TrialThorsten M Leucker, William O Osburn, Paula Reventun, et al.
Contemporary Clinical Trials|May 19, 2007
Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experienceBridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, et al.
European Journal of Heart Failure|July 23, 2022
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trialMarco Metra, Ewa A Jankowska, Matteo Pagnesi, et al.
European Journal of Heart Failure|November 25, 2010
Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study designFriedrich Koehler, Sebastian Winkler, Michael Schieber, et al.
Cardiovascular Diabetology|August 17, 2023
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trialGiuseppe Rosano, Piotr Ponikowski, Cristiana Vitale, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
European Journal of Heart Failure|September 20, 2018
Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the interventionFriedrich Koehler, Kerstin Koehler, Oliver Deckwart, et al.
Nutrients|March 12, 2022
Effects of an Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides on Growth, Tolerability, Safety and Infection Risk in Infants with Cow's Milk Protein Allergy: A Randomized, Multi-Center TrialYvan Vandenplas, Marta Żołnowska, Roberto Berni Canani, et al.
International Journal of Cardiology|October 11, 2011
Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trialFriedrich Koehler, Sebastian Winkler, Michael Schieber, et al.
Circulation|April 13, 2023
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup AnalysisGerasimos Filippatos, Piotr Ponikowski, Dimitrios Farmakis, et al.
European Journal of Heart Failure|April 25, 2017
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysisStefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, et al.
JACC. Basic to Translational Science|December 14, 2021
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized TrialThorsten M Leucker, William O Osburn, Paula Reventun, et al.
Contemporary Clinical Trials|May 19, 2007
Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experienceBridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, et al.
European Journal of Heart Failure|July 23, 2022
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trialMarco Metra, Ewa A Jankowska, Matteo Pagnesi, et al.
European Journal of Heart Failure|November 25, 2010
Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study designFriedrich Koehler, Sebastian Winkler, Michael Schieber, et al.
Cardiovascular Diabetology|August 17, 2023
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trialGiuseppe Rosano, Piotr Ponikowski, Cristiana Vitale, et al.
Pageof 7